- Fungal & Yeast
- Other microbes
The global microbial biopharmaceuticals market was valued round US$ 308 Bn in 2020 and poised to grow at significant CAGR of 14.7% over 2021-2027. microbial biopharmaceuticals market Increase in geriatric population, changes in life styles are increasing the demand for biopharmaceuticals. Increase in research facilities, more approved biopharmaceutical products in market are also key factors effecting the market. Frequent cases of side effects and incompatibilities in cases of mammalian or plant obtained biopharmaceutical products causes the rise in demand for microbial products as they do not possess any side effects. They can be manufactured easily with low cost and are more stable in atmospheric and biological conditions. Microbes have been used to make bread, wine, vinegar, and other common items for millennia, with no one knowing the scientific basis. Nonmicrobial goods such as insulin, interferon, human growth hormone, and viral vaccinations are now commercially produced using genetically altered organisms. Microbes are also employed to produce energy (biodiesel and bioethanol), as well as to clean up contaminants like sewage and oil spills. Microorganisms contribute to increased agricultural production as active ingredients in biofertilizers and biopesticides, and microbes are the foundation of cost-effective mining and metallurgical technologies. Global microbial biopharmaceuticals market is surging owing to frequent acquisitions and launchings by the market players. For Instance, in 2013, Sanofi a French pharmaceutical company announced that a strain of bakerâ€™s yeast capable of producing malaria drugs on an industrial scale had successfully engineered by their researchers and it is commercially available now.
Fastest Growing Market
Microbial biopharmaceuticals are simply defined as the biopharmaceutical products which are extracted from microbial species by using recombinant DNA technology. These products have various benefits when compared to other biopharmaceutical products such as easy manufacture and extraction, low of cost, more stability, high potency, no or very less side effects and high therapeutic nature etc. thus, the market for these microbial biopharmaceuticals are showing significant growth.
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.